- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05458128
En långsiktig säkerhets- och effektivitetsstudie för att utvärdera pitolisant hos vuxna patienter med idiopatisk hypersomni
En öppen studie för att utvärdera den långsiktiga säkerheten och effektiviteten av pitolisant hos vuxna patienter med idiopatisk hypersomni som slutförde studien HBS-101-CL-010
The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) who completed the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 3 open-label study to evaluate the long-term safety and effectiveness of pitolisant in adult patients with IH. Patients who complete the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010 (i.e., completed the End-of-Treatment [EOT] Visit/Visit 5 in the HBS-101-CL-010 study) and who continue to meet eligibility criteria for study HBS-101-CL-011 are eligible for enrollment.
Enrolled patients will be dispensed open-label pitolisant and may be titrated up to a maximum dose of 35.6 mg, based on the Investigator's assessment of safety/tolerability and effectiveness, during a 3-week Titration Period (Day 1 to Day 21) in accordance with the schedule:
- Week 1 (Day 1-7), 8.9 mg
- Week 2 (Day 8-14), 17.8 mg
- Week 3 (Day 15-21), 35.6 mg
The Long-Term Dosing Period will begin on Day 22 and will continue until the patient discontinues from the study or the Sponsor elects to terminate the study (i.e., End-of-Study [EOS]).
An on-site study visit will occur approximately 180 days after Visit 2 on Day 202 (Visit 3). On-site study visits will occur approximately every 6 months and telephone contacts (TCs) approximately every one month in between until the patient withdraws from the study or the study is terminated by the Sponsor. The dose of pitolisant may be adjusted (higher or lower) in increments of 4.45 mg starting at 8.9 mg up to 35.6 mg during the Long-Term Dosing Period based on Investigator assessment of safety/tolerability and effectiveness.
All patients will receive safety follow-up TCs from the study site 15 days and 30 days after their final dose of pitolisant, to assess for adverse events (AEs) and concomitant medication use.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Cedars-Sinai Medical Towers
-
San Ramon, California, Förenta staterna, 94583
- Sleep Medicine Specialists of California
-
-
Florida
-
Brandon, Florida, Förenta staterna, 33511
- Meris Clinical Research
-
Clearwater, Florida, Förenta staterna, 33765
- St. Francis Medical Institute
-
Winter Park, Florida, Förenta staterna, 32789
- Florida Pediatric Research Institute
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30328
- Neurotrials Research Inc.
-
-
Illinois
-
Glenview, Illinois, Förenta staterna, 60026
- NorthShore University Health System
-
Peoria, Illinois, Förenta staterna, 61637
- OSF HealthCare Saint Francis Medical Center
-
-
Michigan
-
Kalamazoo, Michigan, Förenta staterna, 49008
- Western Michigan University Homer Stryker MD School of Medicine
-
Sterling Heights, Michigan, Förenta staterna, 48314
- Clinical Neurophysiology Services
-
-
Missouri
-
Chesterfield, Missouri, Förenta staterna, 63017
- St. Luke's Sleep Medicine and Research Center
-
St Louis, Missouri, Förenta staterna, 63123
- Clayton Sleep Institute
-
-
Nebraska
-
North Platte, Nebraska, Förenta staterna, 69101
- Great Plains Health
-
-
New Jersey
-
Neptune City, New Jersey, Förenta staterna, 07753
- Sleep Dynamics
-
-
New York
-
New Hyde Park, New York, Förenta staterna, 11042
- Northwell Health
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Duke University School of Medicine
-
Gastonia, North Carolina, Förenta staterna, 28054
- Clinical Research of Gastonia
-
Huntersville, North Carolina, Förenta staterna, 28078
- ARSM Research
-
-
Ohio
-
Canton, Ohio, Förenta staterna, 44718
- NeuroScience Research Center, LLC
-
Cincinnati, Ohio, Förenta staterna, 45245
- Intrepid Research, LLC
-
Dublin, Ohio, Förenta staterna, 43017
- Ohio Sleep Medicine and Neuroscience Institue
-
Middleburg, Ohio, Förenta staterna, 44130
- North Star Medical Research
-
-
Pennsylvania
-
Willow Grove, Pennsylvania, Förenta staterna, 19090
- Abington Neurological Associates
-
Wyomissing, Pennsylvania, Förenta staterna, 19610
- Respiratory Specialists
-
-
South Carolina
-
Columbia, South Carolina, Förenta staterna, 29201
- Bogan Sleep Consultants
-
North Charleston, South Carolina, Förenta staterna, 29406
- Lowcountry Lung Critical Care
-
-
Tennessee
-
Cordova, Tennessee, Förenta staterna, 38018
- Neurology Clinic, P.C.
-
-
Texas
-
Austin, Texas, Förenta staterna, 78731
- FutureSearch Trials of Neurology LP
-
Round Rock, Texas, Förenta staterna, 78681
- Central Texas Neurology Consultants, PA
-
Sugar Land, Texas, Förenta staterna, 77478
- Comprehensive Sleep Medicine Associates
-
Tomball, Texas, Förenta staterna, 77375
- Northwest Houston Neurology and Sleep
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53719
- University of Wisconsin-Madison
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Is able to provide voluntary, informed consent.
- Completed the Double-Blind Randomized Withdrawal Phase (EOT/Visit 5) from the HBS-101-CL-010 study.
- A patient who is a female of child-bearing potential must have a negative urine pregnancy test at the Screening Visit. A patient who is a female of child-bearing potential must agree to remain abstinent or use an effective method of non-hormonal contraception to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.
- Must have a negative result on urine drug screen at the Screening Visit, except for medications that are prescribed by a healthcare provider for medical conditions.
- In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and administration of oral study drug.
Exclusion Criteria:
- Does not agree to discontinue any prohibited medication or substances listed in the protocol.
- Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 21 days after final dose of study drug.
- Participation in an interventional research study with an investigational medication or device, other than pitolisant, for the duration of the study.
- Has a diagnosis of end-stage renal disease (ESRD; estimated glomerular filtration rate [eGFR] of <15 mL/minute/1.73 m2) or severe hepatic impairment (Child-Pugh C).
- Is receiving or is unable to discontinue a medication known to prolong the QT interval.
- Has a significant risk of committing suicide or suicidality based on history; routine psychiatric examination; Investigator's judgment; or who has an answer of "yes" on any question other than questions 1 to 3 or "yes" on any question in the suicidal behavior section of the C-SSRS, Since Last Visit.
- Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to an unstable or uncontrolled medical condition or one that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the patient, or compromise the integrity of the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Pitolisant
Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through end of treatment: 17.8 mg to 35.6 mg pitolisant administered once daily in the morning upon wakening. |
Pitolisant 4.45 mg tablets Pitolisant 17.8 mg tablets |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAE)
Tidsram: Up to approximately 3 years
|
A TEAE was defined as any new adverse event or any worsening of a pre-existing condition that was reported after first dose of study drug and up to 30 days after the date of last dose of study drug. |
Up to approximately 3 years
|
|
Change From Baseline in Epworth Sleepiness Scale (ESS) Score
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher scores represent more severe daytime sleepiness. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Score
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
|
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
|
Change From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S [EDS]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
|
Change From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) Score
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-Score
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from 1 to 5. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40. T-score ranges from 30 to 80.1. Higher scores represent greater impairment. HealthMeasures reports that PROMIS-SRI SF 8a T-score mean is 50 with a standard deviation of 10 in the general population. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
|
Change From Baseline in Sleep Inertia Questionnaire (SIQ) Score
Tidsram: Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
The Sleep Inertia Questionnaire (SIQ) score is the sum of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia. |
Baseline, Week 4 and Months 7, 13, 19, 25, 31
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HBS-101-CL-011
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .